Holen Sie sich die Stockscreener-App
112.40
6.13%
6.495
Handel nachbörslich:
114.00
1.60
+1.42%
Schlusskurs vom Vortag:
$105.91
Offen:
$107.5
24-Stunden-Volumen:
160.79K
Relative Volume:
2.62
Marktkapitalisierung:
$3.58B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-95.72
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
+19.80%
1M Leistung:
+48.68%
6M Leistung:
+79.38%
1J Leistung:
+60.80%
1-Tages-Spanne:
$107.00
$115.41
1-Wochen-Bereich:
$90.77
$115.41
52-Wochen-Spanne:
$49.00
$115.41
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
112.40 | 3.70B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Belite Bio (NASDAQ: BLTE) to host third-quarter results webcast at 4:30 p.m. ET - Stock Titan
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of... - markets.businessinsider.com
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant - GlobeNewswire
Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Belite Bio stock hits all-time high at 101.92 USD By Investing.com - Investing.com Australia
Belite Bio stock hits all-time high at 101.92 USD - Investing.com
Can machine learning forecast Belite Bio Inc Depositary Receipt recoveryIndex Update & Consistent Growth Equity Picks - newser.com
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
How Belite Bio Inc Depositary Receipt stock performs during Fed tightening cyclesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Belite Bio to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference November 4th - GlobeNewswire
Belite Bio (NASDAQ: BLTE) to present 10:30 ET at ADR Virtual Investor Conf.; 90-day replay - Stock Titan
How Belite Bio Inc (Common Stock) (D01) stock valuation compares with sectorJuly 2025 Update & Reliable Entry Point Trade Alerts - fcp.pa.gov.br
Risk vs reward if holding onto Belite Bio Inc Depositary ReceiptJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Why Belite Bio Inc Depositary Receipt stock could benefit from AI revolution2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
Belite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will Belite Bio Inc (Common Stock) (D01) stock outperform energy sector in 2025Earnings Trend Report & Stepwise Entry and Exit Trade Signals - newser.com
Belite Bio stock reaches all-time high at 92.12 USD By Investing.com - Investing.com Nigeria
Belite Bio stock reaches all-time high at 92.12 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Should You Buy? - Defense World
Is Belite Bio Inc Depositary Receipt stock a safe investment in uncertain markets2025 Market WrapUp & Technical Pattern Based Buy Signals - nchmf.gov.vn
Belite Bio stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Belite Bio (NASDAQ:BLTE) Trading Up 6.7%Should You Buy? - MarketBeat
(BLTE) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Belite Bio stock hits all-time high at 86.61 USD By Investing.com - Investing.com Philippines
Belite Bio to Participate in the 2025 Maxim Growth Summit - markets.businessinsider.com
Belite Bio stock hits all-time high at 86.61 USD - Investing.com
Belite Bio Stocks Surge Amid Drug Approval Hopes - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Consensus Target Price from Brokerages - Defense World
Eagle Point Credit Company Inc. (NYSE:ECC) Receives $8.21 Average Price Target from Analysts - Defense World
Oct. 22, 2025: Belite Bio to Participate in Maxim Growth Summit; meetings available via Maxim rep - Stock Titan
Phase 3 interim prompts China NMPA Priority NDA Review — Belite Bio's Tinlarebant; topline Q4 2025 - Stock Titan
Cango Inc. to Terminate ADR Program and List Class A Ordinary Shares Directly on NYSE - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - Yahoo Finance
Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI) - The Globe and Mail
What MACD signals say about Belite Bio Inc Depositary Receipt2025 Top Gainers & Real-Time Market Trend Scan - newser.com
GAMMA Investing LLC Trims Stock Holdings in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
3 Lesser-Known Healthcare Names With Major Upside in Store - MarketBeat
Volume spikes in Belite Bio Inc Depositary Receipt stock – what they mean2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Juvenile Macular Degeneration Pipeline 2025: Innovative Clinical Developments by 80+ Global Leaders – DelveInsight | Highlighting Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen - Barchart.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeHere's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Upgraded at Wall Street Zen - MarketBeat
Stargardt Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Belite Bio (NASDAQ:BLTE) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Analysts Set Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) PT at $96.00 - MarketBeat
HC Wainwright Has Positive Outlook of Belite Bio Q3 Earnings - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Average Target Price from Analysts - Defense World
Lin BioScience Subsidiary Belite Completes LBS-008 STGD1 Phase III Trial, Secures NT$8.4 Billion Private Placement - 全球醫療採購網
HC Wainwright Has Lowered Expectations for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):